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Hexamethylbisacetamide (HMBA) induces human immunodeficiency virus type 1 (HIV-1) gene expression
in latently infected T-cell and monocytoid cell lines. We find that HMBA activation of viral expression is Tat
independent but, like Tat, increases the efficiency of elongation of the HIV-1 promoter (long terminal repeat
[LTR]) transcripts. Further, exposure to HMBA induces chromatin remodeling at nucleosome 1 (Nuc-1) near
the start site of LTR transcription but does so without increasing histone acetylation or altering histone
methylation near Nuc-1. Of note, despite enhanced proviral expression, HMBA suppressed HIV infection ex
vivo in primary blood mononuclear cell (PBMC) cultures. Treatment with HMBA did not alter expression of
the HIV coreceptors, CCR5 and CXCR4, in PBMCs but down-regulated CD4. Finally, HMBA interferes with
cell proliferation and activation; it suppressed expression of Ki67 and CD25 and in PBMCs exposed to
mitogen. As HMBA has been tested in oncology trials, its unusual properties make it a useful reagent for future
studies of HIV promoter regulation and a novel prototype molecule for therapeutics that abort the latent
proviral state of chronic HIV infection.
The introduction of highly active antiretroviral therapy
(HAART) raised hopes for eradication of established human
immunodeficiency virus (HIV) infection. This hope dimmed
when latently infected CD4 lymphocytes were found to per-
sist in individuals despite years of viral suppression (11, 24, 75).
Latent infection of memory T cells is established early after
infection (12) and is unaffected by the antiviral immune re-
sponse or antiviral therapies (15). The slow rate of disappear-
ance of these cells during antiretroviral therapy led to esti-
mates that eradication of infection would require decades of
continuous therapy (23, 51, 63).
Activation of quiescent cells in the presence of HAART to
drive latently infected cells out of the resting state has been
explored as a therapeutic strategy. Unfortunately, intensive
antiretroviral therapy in combination with the administration
of interleukin-2 (IL-2) and/or anti-CD3 monoclonal antibody
does not eradicate HIV infection (13, 18, 35, 49, 64, 71). Re-
cently alternative strategies to disrupt latent HIV infection
through the use of histone deacetylase (HDAC) inhibitors,
IL-7, resveratrol, and prostratin have been proposed (7, 17, 34,
39, 40, 78).
Hexamethylbisacetamide (HMBA) was developed as an an-
ticancer drug (54) as it can induce differentiation of leukemic
and solid tumor cell lines (28, 42, 43, 58). Suboptimal antitu-
mor activity at clinically tolerable doses has impeded the fur-
ther development of HMBA (2).
HMBA is known to activate HIV expression in chronically
infected cell lines (3, 62, 74) and in cell lines stably transfected
with long terminal repeat (LTR)-reporter gene constructs (66,
81). While HMBA is structurally related to HDAC inhibitors,
it does not inhibit HDACs or induce histone hyperacetylation
(56). Indirect evidence suggests that HMBA and HDAC in-
hibitors induce cell differentiation by different pathways (57).
Tumor cell lines resistant to the differentiation-inducing activ-
ity of HDAC inhibitors are not resistant to HMBA (56). The
molecular mechanism underlying HDAC inhibitor induction
of HIV expression is understood in some detail (17, 59, 70, 79).
However, the mechanism by which HMBA induces HIV pro-
viral expression has not been elucidated (80).
In contrast to inducers such as tumor necrosis factor alpha
and phorbol-12-myristate-13-acetate, HMBA-mediated induc-
tion of HIV-1 expression does not require NF-B binding sites
at the HIV-1 LTR, whereas Sp1 binding sites are required
for HMBA response (3, 74). HMBA mediates a number of
changes in cellular metabolism (6, 26, 41, 44, 45) and induces
expression of globin genes and changes in expression of the
proto-oncogenes c-myb, c-myc, c-fos, and p53 (9, 52). Treat-
ment with HMBA blocks cell cycle progression in G1. It also
induces a rapid decrease in the cdk4 protein level, followed by
suppression of cdk4-associated pRB kinase activity and an
increase in cyclin D3 (32).
We sought to expand our understanding of the mechanisms
through which HMBA induces expression of quiescent HIV
provirus. We find that HMBA increases both initiation and
elongation of the HIV-1 LTR in the absence of Tat. Surpris-
ingly, HMBA increased DNA accessibility and induced nucleo-
some remodeling without histone acetylation. However, unlike
mitogen activation, HMBA did not increase cell susceptibility
to HIV infection or the expression of cell surface markers of
activation. In fact, HMBA down-regulated the surface expres-
sion of the HIV receptor, CD4. As a likely result of this effect,
HMBA did not enhance de novo cell infection, and it sup-
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pressed HIV propagation in ex vivo primary blood mononu-
clear cell (PBMC) cultures.
In summary, our findings suggest that HMBA is a novel
prototype for therapeutics designed to interrupt latent HIV
infection.
MATERIALS AND METHODS
Cell culture and viral stocks. PBMCs were separated from whole blood of
healthy donors by density centrifugation with Ficoll Histopaque (Amersham,
Piscataway, NJ). PBMCs were cultured in medium consisting of Iscove’s modi-
fied Dulbecco’s medium (Invitrogen, Carlsbad, CA) supplemented with 10%
heat-inactivated fetal bovine serum (FBS) (Cellgro, Herndon, VA), 2 mM glu-
tamine, penicillin/streptomycin (Invitrogen), and 20 U/ml recombinant IL-2
(Sigma, St. Louis, MO).
THP89GFP and J89GFP cell lines were obtained from D. Levy (36). The
HeLa-CD4-LTR cell line (16, 76), HLM1 cell line (60, 61), U1 cell line (25), and
HIV-1 molecular clone pNL4-3 (1) were obtained from the National Institutes of
Health AIDS Research and Reference Reagent Program repository. Cells were
grown and maintained as previously described (1, 16, 25, 36, 60, 61, 76). Virus
stock was prepared by transient transfection of 293T cells, and p24 production
was measured by enzyme-linked immunosorbent assay (Coulter, Miami, FL).
Flow cytometry analysis. Conjugated antibodies used for fluorescence-acti-
vated cell sorting (FACS) included the following: anti-CD3-peridinin chlorophyll
protein, anti-CD3-fluorescein isothiocyanate (FITC), anti-CD4-allophycocyanin,
anti-CCR5-FITC, anti-HL-DR-FITC, anti-CD69-phycoerythrin (PE), anti-CD38-
PE, anti-CD25-PE, anti-Ki67-FITC (all from BD Pharmingen, San Diego, CA), and
anti-p24-FITC (Coulter, Miami, FL). A total of 1  106 PBMCs were washed twice
with ice-cold 2% FBS–phosphate-buffered saline (PBS) and stained in 0.1 ml of
PBS-FBS with a cocktail of antibodies for surface markers or isotype control in the
dark for 30 min at 4°C. Stained cells were fixed and permeabilized (Fix and Perm Kit;
Caltag Laboratories, Burlingame, CA) and restained for intracellular markers at
room temperature for 20 min. FACS was performed on a FACSCalibur, and data
were analyzed with Cellquest software (Becton Dickinson, San Jose, CA). For the
analysis, total lymphocytes were first identified and gated by forward and side scatter.
A total of 10,000 gated events were collected for each sample.
PBMC infections. PBMCs obtained from HIV-seronegative donor buffy coats
were stimulated with 2 g/ml of phytohemagglutinin (PHA) (Remel, Lanexa,
KS) in Iscove’s modified Dulbecco’s medium supplemented with 10% FBS and
20 U/ml of IL-2 for 3 days. Stimulated cells were washed, and 1  106 PBMCs
per condition were infected with viral stock (50 ng of p24) in 0.2 ml for 1 h.
PBMCs were washed and cultured at a density of 1  106 cells/ml. After 3 days
cells were washed twice with 2% FBS–PBS, fixed, permeabilized, and stained
with antibody against p24 HIV antigen, and cells positive for intracellular p24
were quantitated by flow cytometry.
ChIP assay. Anti-acetyl-H3, anti-acetyl-H4, and anti-dimethyl-lysine 4-H3
were purchased from Upstate Biotechnology (Lake Placid, NY). Antibodies
recognizing amino acids 124 to 135 of H3 were purchased from Abcam (Cam-
bridge, MA). Immunoprecipitation of chromatin was performed using a chro-
matin immunoprecipitation (ChIP) assay kit (Upstate Biotechnology) according
to the manufacturer’s protocol. Immunoprecipitated DNA was quantitated by
PCR using two sets of primers: LTR-109F (5-TACAAGGGACTTTCCGCTG
G-3) and LTR82R (5-AGCTTTATTGAGGCTTAAGC-3) for the HIV-1
promoter and CCR5F (5-TACCTGCTCAACCTGGCCAT-3) and CCR5R
(5-TTCCAAAGTCCCACTGGGC-3) for the CCR5 receptor. A total of 30
PCR cycles were carried out with 2 to 10 l of precipitated DNA in a 25-l
reaction mixture containing 12.5 l of master mix (QIAGEN, Valencia, CA) and
a 400 nM concentration of each primer. PCR products were resolved by 8%
polyacrylamide gel electrophoresis and visualized by ethidium bromide staining.
Images of gels were quantified using AlphaImager 2000 with Alpha Ease FC
software (Alpha Innotech Corp., San Leandro, CA). Serial twofold dilutions of
input DNA were also subjected to PCR to ensure linear amplification in each
experiment. All values represent the average of at least three independent
experiments. Differences were compared using a two-tailed Student’s t test as-
suming independence of variance.
Analysis of LTR nucleosome 1 (Nuc-1) chromatin structure. Restriction en-
zyme digestion of purified nuclei with AlfII and HinfI was performed as previ-
ously described (70, 73). Thirty micrograms of purified DNA per condition was
digested to completion with PstI, and the fragments were separated by electro-
phoresis in 1.5% agarose. Digoxigenin-labeled probe A (see Fig. 1) (72) was used
for Southern blot analysis. The probe was generated using the primer set EV1
and EV2 (72) and a PCR DIG Probe Synthesis Kit (Roche Applied Science,
Indianapolis, IN). Alkaline phosphatase-conjugated antibody and chemilumines-
cent CDP-Star substrate (Roche Applied Science) were used for detection. Blots
were exposed to X-ray film, and images were quantified using AlphaImager 2000
with Alpha Ease FC. All values represent the average of least three independent
experiments. Differences were compared using a two-tailed Student’s t test as-
suming independent variance.
Real-time PCR assay. Total RNA was isolated from cells using Triazol (In-
vitrogen, Carlsbad, CA) and treated with DNase I amplification grade (Invitro-
gen). cDNA was synthesized in the presence of 0.75 M concentrations of the
gene-specific primers (37) HIV-SHORT-RT (5-GGGTTCCCTAGTT-3) and
HIV-Long-RT (5-CGCCACTGCTAG-3) and 5 g/ml concentrations of ran-
dom hexamers (Invitrogen) using Moloney murine leukemia virus reverse trans-
criptase according to the manufacturer’s protocol (Promega, Madison, WI).
Real-time PCR for detection of total and elongated HIV-1 transcripts was
performed using a modified version of a previously described set of primers (30,
37): HIV-START-M, 5-GGTCTCTCTGGTTAGACCAGATCTGAGCC-3;
HIV-SHORT-M, 5-GGGTTCCCTAGTTAGCCAGAGAGCTCC-3; and HIV-
LONG-M, 5-CGCCACTGCTAGAGATTTTCCACACTGAC-3. As an input
control, a primer set that detects glyceraldehydes-3-phosphate-dehydrogenase
(GAPDH) mRNA was used (GAPDH-F, 5-TCACCACCATGGAGAAGGCT
GGG-3; GAPDH-RA, 5-GGCATCAGCAGAGGGGGCAGA-3). PCR was
performed by heating the reaction mixture to 95°C for 10 min, followed by 45
cycles at 95°C for 15 seconds and 60°C for 1 min. Amplification and detection
were performed using an ABI Prism 7700 Sequence Detector system and SYBR
Green PCR Master Mix (Applied Biosystems, Foster City, CA). Triplicate 50-l
reaction mixtures contained 200 pg of cDNA and a 400 nM concentration of each
PCR primer. Changes in transcript concentrations were estimated using the
comparative cycle threshold method.
CAT assay. HeLa-CD4-LTR-chloramphenicol acetyltransferase (CAT) cells
were transfected with plasmids pCMV-Tat (where CMV is cytomegalovirus),
encoding the HIV Tat protein, or control vector pCMV using Lipofectamine
(Invitrogen, Carlsbad, CA), according to the manufacturer’s protocol. Each
FIG. 1. HMBA activates the HIV LTR expression of HeLa-CD4-
LTR-CAT cells. Cells transfected with control vector pCMV (lanes 1
to 3) or with plasmid pCMV-Tat, encoding HIV Tat protein (lane 4).
After transfection cells were cultured in medium alone (lanes 1 and 4),
treated with 400 nM TSA (lane 2), or treated with 5 mM HMBA (lane
3). The level of LTR-driven CAT expression, normalized to the back-
ground level of CAT expressed in the absence of Tat, is indicated. Cm,
chloramphenicol; bCm, butyrlated chloramphenicol. Results are rep-
resentative of three independent transfections.
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transfection used 5 g of total DNA. Drugs were added 4 h after transfection,
and all cultures were then incubated for 24 h with 10% FBS in a 5% CO2
incubator. Cells were then washed and treated with trypsin, and cell lysates were
made as previously described (29). Extracts were normalized for protein content,
and thin-layer chromatography CAT assays were performed (Promega, Madison,
WI). Silica plates were exposed to X-ray film, and densitometric quantification of
the CAT activities was performed using the AlphaImager 2000 with Alpha Ease
FC software.
Limiting dilution cultures of latently infected CD4 T cells from HIV-positive
donors. Lymphocytes were obtained by continuous-flow leukopheresis from sta-
ble, HIV-infected volunteers on antiretroviral therapy with plasma HIV-1 RNA
levels of 50 copies/ml for more than 12 months and CD4 cell counts of 300
cells/l. Human Subjects Committee-approved informed consent was obtained
from all patients. Isolation of CD4 T cells and recovery and quantification of
replication-competent HIV were performed as described in detail previously (14,
39, 78). After isolation of resting CD4 cells and treatment as described, cells
were activated or exposed to HMBA for 72 h. Cells were then fed with fresh
medium and target feeder cells and cultured as detailed previously (78).
RESULTS
HMBA activation of HIV LTR is Tat independent. In la-
tently infected resting T cells, HIV provirus transcription is
absent or persists at very low levels. Ideally, drugs that inter-
rupt HIV latency should be able to stimulate basal expression
by Tat-independent mechanisms. Early studies differed as to
the ability of HMBA to induce HIV expression in the absence
of Tat (62, 72). To resolve these uncertainties, we studied the
FIG. 2. HMBA induces LTR expression in latently infected cell lines. Enhanced green fluorescent protein expression of THP89GFP (A) and
J89GFP (B) cells that possess functional Tat and p24 antigen production of HLM1 cells that lack Tat (C) treated with 1 and 5 mM HMBA. Viability
of cells shown in panels A, B, and C is given in panels D, E, and F, respectively. Viability of PBMCs treated with HMBA is shown in panel G.
MFI, mean fluorescence intensity. Times after HMBA exposure are indicated as follows: open bars, 24 h; gray bars, 48 h; black bars, 72 h. Results
are representative of three independent experiments.
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effect of HMBA in cell lines stably transfected with an LTR-
reporter gene construct and three cell lines carrying HIV pro-
virus with functioning and defective Tat activation pathways.
HeLa-CD4-LTR-CAT cells, which carry one copy of an
LTR-reporter gene construct, were used to compare the effect
of HMBA to the HDAC inhibitor, trichostatin A (TSA), and
viral transactivator Tat. We found that both HMBA and TSA
induced LTR expression, but levels of induction in cells ex-
posed to HMBA or TSA were much lower than the level
following Tat activation (Fig. 1).
HMBA enhanced LTR expression in both the J89GFP
Jurkat T-cell line and monocytoid THP89GFP cell line, which
carry a single copy of provirus with functioning Tat (Fig. 2A
and B). Further, HMBA strongly enhanced Tat-deficient pro-
virus expression and virion production in the HLM1 cell line
(Fig. 2C). Thus, HMBA is able to increase the basal level of
HIV-1 expression through a Tat-independent mechanism.
Exposure to 1 to 5 mM HMBA induces HIV expression in
latently infected cell lines, with most studies finding maximal
induction at 5 mM (3, 62, 74). We reevaluated the effect of 0.2
to 25 mM HMBA in PBMCs and cell lines chosen for our
studies and confirmed that 5 mM HMBA induces maximal
expression without an appreciable effect on cell viability (Fig.
2D to G).
HMBA increases the rate of initiation of HIV-1 transcrip-
tion. In the absence of Tat, HIV transcription pauses at a point
downstream of the transcription initiation site, in the transac-
tivation response element (TAR). Tat increases the efficiency
of elongation (22) and stimulates transcription complex assem-
bly (50). We analyzed the temporal profile of expression of
paused and elongated transcripts in HLM1 cells treated with
HMBA compared to the HDAC inhibitor TSA (Fig. 3). An
increase in HIV RNA expression was detected after only 2.5 h
of treatment (P  0.05), and maximal induction was reached at
5.5 h of treatment. TSA and HMBA increased the initiation
rate 2.2- and 3.6-fold, respectively, and elongated transcripts
increased 3.9- and 7.1-fold, respectively (Fig. 3). These results
show that TSA and HMBA enhance elongation beyond TAR,
augmenting HIV expression in the absence of Tat.
HMBA induces HIV-1 LTR chromatin remodeling. The nu-
cleosome positioned near the start site of HIV LTR transcrip-
tion (Nuc-1) presents an elongation barrier to polymerase, and
its remodeling plays a role in the reactivation of the HIV
promoter from latency (69). Histones within Nuc-1 are remod-
eled by acetylation upon stimulation in response to Tat, mito-
gens, and HDAC inhibitors (19, 70, 73).
We examined changes in histone modification at Nuc-1 after
2.5 h of HMBA treatment of J89GFP and THP89GFP cells by
using a ChIP assay with antibodies specific for acetylated H3,
acetylated H4, and dimethylated lysine 4 of H3. Performing the
ChIP assay after a short period of HMBA exposure makes it
unlikely that secondary, nonspecific effects will be observed.
Precipitated DNA was analyzed by PCR with primers spanning
the Nuc-1 region and the CCR5 receptor gene. Amplification
of serial dilutions of DNA demonstrated that a twofold in-
crease in density of the PCR product band represents more
than a threefold increase in target DNA (Fig. 4A). It is impor-
tant to point out that the semiquantitative nature of these
assays allows us to qualitatively measure significant changes in
occupancy but not to compare the relative quantity of different
histone modifications. As expected, TSA induced acetylation
of H3 and H4 and dimethylation of H3 lysine 4. Surprisingly,
we found that H3 and H4 acetylation and H3 lysine 4 methyl-
ation were not altered in J89GFP lymphocytic cells treated
with HMBA (Fig. 4B and C). Similar results were seen in
THP89GFP monocytoid cells. Although HMBA appeared to
reproducibly decrease the acetylation of H3 in a statistically
significant way, it is difficult to demonstrate that such a de-
crease is quantitatively significant.
Taken at face value, our results would suggest that, contrary
to the histone code hypothesis (31, 65, 67), histone acetylation
at the Nuc-1 of the HIV-1 LTR is largely unchanged after
HMBA exposure, despite the induction of transcription. How-
ever, another possible interpretation of these findings is that
HMBA induces a rapid loss of contact of histones with DNA at
Nuc-1. This phenomenon has recently been observed in other
systems (38, 53).
To test whether histone occupancy was lost at Nuc-1 follow-
ing exposure to HMBA, we measured occupancy of total H3 at
Nuc-1 using an antibody that recognizes an unmodified epitope
at the carboxy terminus of histone H3. We did not detect
changes in H3 occupancy at Nuc-1 in either cell line (J89GFP
or THP89GFP) after HMBA and TSA treatment compared to
FIG. 3. Temporal profile of initiation and elongation rates of pro-
viral transcription in HLM1 cells treated with 5 mM HMBA (A) and
400 nM TSA (B). Changes in concentrations of total and elongated
transcripts were measured by real-time reverse transcription-PCR.
Graphs indicate changes in concentrations (conc) of all LTR tran-
scripts (both short, nonprocessive and full-length; open bars) and full-
length transcripts (gray bars). Results are representative of three in-
dependent experiments.
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untreated control cells (Fig. 4). Thus, the lack of upregulation
of histone acetylation after HMBA exposure and LTR expres-
sion is not the result of the complete loss of histones from this
region of chromatin.
An alternative explanation is that HMBA induces novel his-
tone modifications which result in increased DNA accessibility.
Methylation of lysine 4 in H3 is associated with activation of
transcription (27, 33), and we found that activation of the HIV-1
promoter with TSA was accompanied by dimethylation of lysine
4 of H3. However, no changes were detected at the level of
dimethylation in HMBA-treated cells (Fig. 4B and C).
Chromatin remodeling at the HIV-1 promoter can result in
increased accessibility of the DNA to nucleases (70–73). In
order to directly examine chromatin accessibility, we deter-
mined the susceptibility of the HIV-1 LTR to restriction en-
donucleases following exposure to HMBA. The chronically
FIG. 4. Activation of HIV expression with HMBA is not accompanied by histone modification at the 5 LTR Nuc-1. (A) Semiquantitation of
ChIP assay. Twofold increases in DNA input result in less than a twofold increase in PCR product. We therefore consider any twofold change in
PCR band density to represent a significant qualitative change in occupancy. Chromatin isolation for ChIP analysis was performed after 2.5 h of
drug exposure. (B) Histone modifications within Nuc-1 as detected by ChIP assay in THP89GFP and J89GFP cells treated with 400 nM TSA or
5 mM HMBA. Antibodies used in ChIP assays against acetylated H3, acetylated H4, dimethylated lysine 4 of H3, and total H3 are shown at left.
(C) Relative levels of histone modification and total level of H3 averaged from three independent ChIP experiments. Statistically significant
changes are indicated by an asterisk (P  0.05). Open, light gray, dark gray, and black bars are relative levels of H3 acetylation, H4 acetylation,
lysine 4 of H3 dimethylation, and total H3, respectively. Untr, untreated.
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infected U1 cell line, carrying two copies of proviruses, each
with defective Tat transactivating genes (20, 21), were used to
assess the effect of HMBA.
After treatment of U1 cells with HMBA or TSA for 5 h,
nuclei were isolated and digested with AlfII or HinfI, which
have cleavage sites in the Nuc-1 region (Fig. 5A). DNA was
purified from the nuclei and digested to completion with PstI,
which has a recognition site downstream of the LTR sequence.
The digested products were analyzed by Southern blotting
(Fig. 5B). TSA was used in these experiments as a positive
FIG. 5. HMBA induces HIV LTR Nuc-1 remodeling. (A) Diagram shows the position of nucleosomes and the location of restriction enzyme
sites and the probe used for Southern blotting (73). Letters identify the restriction fragments shown in panel B. (B) U1 cells were treated for 5 h
with 400 nM TSA or 5 mM HMBA; nuclear DNA was partially digested with AlfII or HinfI, digested to completion with PstI, and analyzed by
Southern blotting. M, molecular weight marker III. (C) Densitometric quantification of the accessibility of DNA at the Nuc-1 region after TSA
(open bars) or HMBA (gray bars) treatment, relative to untreated cells. Results are representative of three independent experiments. (D) Histone
modifications within Nuc-1 as detected by ChIP assay in U1 cells treated with 400 nM TSA or 5 mM HMBA for 4 to 5 h. Antibodies used in ChIP
against acetylated H3 and acetylated H4 are indicated at left. Results are representative of three independent experiments. IP, immunoprecipi-
tation.
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control, as Nuc-1 disruption has been demonstrated following
HDAC inhibitor treatment (70). We found that the region
corresponding to Nuc-1 became accessible to digestion by re-
striction enzymes following treatment with HMBA. The in-
crease in accessibility of the underlying DNA in Nuc-1 is sim-
ilar to that observed after TSA treatment. This effect was
specific for the Nuc-1 region because, in marked contrast,
restriction by HinfI in the nucleosome-free region was not
enhanced by either treatment. Strikingly, unlike TSA, HMBA
did not induce acetylation of chromatin, typically associated
with nucleosome mobilization, and uniformly associated with
activation of the HIV LTR (Fig. 5D).
HMBA suppresses CD4, Ki67, and CD25 expression in ac-
tivated PBMCs but does not affect expression of HIV corecep-
tors or other surface markers of activation. Reagents used to
reactivate latent HIV should not simultaneously increase the
susceptibility of cells to new rounds of infection. Therefore, we
investigated the effect of HMBA on the expression of CD4 and
HIV coreceptors in human PBMC ex vivo cultures. Four cul-
ture conditions were used in this experiment. PBMCs were
stimulated with 2 g/ml PHA for 3 days in the presence or
absence of HMBA. Non-PHA-stimulated PBMCs were also
cultured for 3 days with or without 5 mM HMBA. FACS
analysis showed that HMBA down-regulated surface CD4 ex-
pression, particularly after PHA stimulation. HMBA had little
effect on CCR5 and CXCR4 expression (Fig. 6).
As cell cycle and activation state also influence the efficiency
of productive viral infection, we investigated the influence of
HMBA on markers of activation and proliferation. HMBA
completely suppressed PHA-mediated upregulation of the in-
tracellular proliferation marker Ki67 and abolished the PHA-
induced expression of the activation marker CD25, the alpha
chain of the IL-2 receptor. In contrast, expression of CD38,
CD69, and HLA-DR were not significantly altered by HMBA
(Fig. 6). These findings suggest that HMBA may induce HIV
proviral expression but interfere with the propagation of viral
infection.
HMBA suppresses de novo infection in cultured PBMCs. To
examine the possibility that HMBA inhibits HIV infection, we
studied infection in PBMC cultures. PBMCs were stimulated
with PHA for 3 days and infected with a virus generated from
a CXCR4-tropic HIV molecular clone (NL4-3) in medium
with or without HMBA. After 1 h of infection, the cells were
washed and cultured in medium with or without HMBA. On
day 3 after infection, intracellular p24 expression was mea-
sured by flow cytometry (Table 1). The presence of HMBA
during infection did not affect virus production, but viral ex-
pression was substantially reduced when infected cells were
cultured in the presence of HMBA. This finding suggests that
HMBA did not directly inactivate virus, but its effects on CD4
expression and/or cell proliferation substantially inhibited virus
propagation over time in culture.
We then tested the ability of HMBA to induce expression of
quiescent provirus in resting CD4 T cells obtained from avire-
mic, HAART-treated, HIV-infected donors, as described pre-
viously (39, 40). While virus was recovered from the cells of
three donors when maximally activated by PHA and irradiated
allogeneic cells, exposure to 0.5 to 5 mM HMBA rarely re-
sulted in the recovery of HIV from these patients’ resting
CD4 T cells. This result might be explained by weak induc-
tion of proviral outgrowth at lower HMBA concentrations and,
at higher HMBA concentrations, by the inhibition of viral
spread required to detect rare replication-competent HIV in
this ex vivo outgrowth system.
DISCUSSION
HMBA induces HIV expression in chronically infected T
lymphocytic (ACH-2) and monocytoid (U1) cell lines with
defects in the Tat activation axis (20, 21, 74). HMBA also
activates expression of the LTR in the absence of Tat in cells
stably transfected with LTR-reporter gene constructs (66, 81).
We find that HMBA enhances Tat-independent transcrip-
tion in cell lines carrying an LTR-reporter gene construct and








Without 5 mM HMBA 0.07  0.02
With 5 mM HMBA 0.14  0.05
HIV NL4-3
Without 5 mM HMBA 18.39  1.57
With 5 mM HMBA 2.69  0.55 6.84  1.51
a Decrease is the difference between the percentages of cells cultured without
and with HMBA.
FIG. 6. HMBA does not increase cell activation or expression of
HIV receptors and coreceptors. PBMCs were stimulated with 2 g/ml
PHA in the presence or absence of 5 mM HMBA for 3 days. Unstimu-
lated PBMCs were cultured for this time in medium with or without
HMBA. Flow cytometry analysis was performed at 3 days after stim-
ulation to evaluate the levels of expression of viral receptor, corecep-
tors, and activation markers. Dual-parameter plots demonstrate the
effect of HMBA on the expression of CD25 and Ki67 in panel A and
CD4 and CXCR4 in panel B. Numbers displayed in each quadrant of
these plots are percentages of positive cells. In panel C results of flow
cytometry analysis are presented as histogram plots. The results shown
are representative of three different experiments with PBMCs from
three donors.
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in a latently HIV-infected HIV-1 cell line, HLM1 (Fig. 2). As
expected, the level of activation with HMBA in HeLa-CD4-
LTR-CAT reporter cell lines is lower than that induced by Tat
(Fig. 1). Further, real-time reverse transcription-PCR analysis
examining the mechanism of activation of LTR expression
found that both HMBA and TSA enhance initiation and elon-
gation beyond TAR in the absence of Tat (Fig. 3). Tat in-
creases elongation by recruiting the positive transcriptional
elongation factor b (p-TEFb) with subsequent phosphorylation
of the C-terminal domain of RNA polymerase II. However,
although HMBA appears to exert a similar transcriptional
phenotype, HMBA has been shown to inhibit transcription
mediated by p-TEFb by inducing the expression of the p-TEFb
cellular inhibitor HEXIM1 (77). Further study is needed to
elucidate the unique mechanism by which HMBA induces HIV
LTR expression.
Dynamic changes in chromatin are thought to induce ex-
pression, in part by making DNA more accessible to tran-
scription factors. Two general classes of multiprotein com-
plexes remodel chromatin by modifying the core histone
tails (31, 65, 67) or using ATP hydrolysis to alter chromatin
structure (4, 48).
In our experiments, using a nuclease accessibility assay to
assess the state of chromatin, we found that HMBA induced
LTR Nuc-1 remodeling to the same extent as does the HDAC
inhibitor TSA (Fig. 5). Strikingly, in contrast to HDAC inhib-
itors or tumor necrosis factor alpha (19, 70, 73), HMBA does
not induce histone hyperacetylation or alter dimethylation of
H3 lysine 4 at Nuc-1 (Fig. 4). Chromatin remodeling could
cause the dissociation of histones from a promoter region,
resulting in an apparent absence of or decrease in the histone
modification signal (e.g., acetylation) measured by a ChIP as-
say. In Saccharomyces cerevisiae, nucleosome occupancy at
proximal gene regulatory regions is inversely proportional to
the transcriptional initiation rate of the promoter (38, 53).
Similarly, at the mammalian IL-2 and granulocyte-macrophage
colony stimulation factor promoters, apparent loss of histone
acetylation and phosphorylation was found to be caused by
decreased nucleosome occupancy (10). We found that HMBA
did not alter histone H3 occupancy, and so our results cannot
be explained by a general loss of histones at the 5 LTR.
Another explanation for the finding that HMBA increased
DNA accessibility without typical increases of acetylation is
that other modifications of histone structure render the prox-
imal LTR susceptible to nuclease restriction. Recently, the
potential of SWI/SNF complex to cause an ATP-dependent
increase in histone exchange was demonstrated in yeast (8).
Perhaps HMBA stimulates similar ATP-dependent remodel-
ing. Although HMBA-mediated remodeling of the LTR Nuc-1
might be a downstream effect of HMBA action, its rapid onset
of action makes this less likely.
The cellular effects of HMBA differ from other reagents that
induce the expression of latent HIV. HDAC inhibitors do not
alter the expression of activation markers on the surface lym-
phocytes (78), while prostratin enhances the expression of
CD25 and CD69 (5). HMBA, however, down-regulates the
activation marker CD25 and the proliferation marker Ki67 in
PBMCs. Similar to prostratin, HMBA decreased expression of
viral receptor CD4 but, unlike prostratin, only slightly affected
the expression of viral coreceptors CXCR4 and CCR5. HDAC
inhibitors do not enhance de novo HIV infection (78). Pros-
tratin restricts viral entry and reverse transcription but facili-
tates integration of the HIV genome in nondividing CD4 T
cells (5). Here, we found that HMBA significantly inhibits
HIV-1 infection in PBMCs. Our data suggest that HMBA may
interfere with completion of the other steps of the viral cycle.
Remarkably, induction of the IL-2 receptor CD25 in PBMCs
stimulated with PHA was abolished in the presence of HMBA
(Fig. 6). This is reminiscent of the effect of antibodies against
CD25 that block IL-2 signaling (46, 68).
As HMBA induces cell differentiation, it seems plausible
that affected cellular regulatory factors might also induce HIV
promoter activity. In a teratocarcinoma cell line, Zeichner and
colleagues found evidence that factors binding to sites located
at the HIV core promoter and enhancer played a role in the
HIV LTR response to HMBA (47, 81).
In summary, our results indicate that HMBA is able to
activate HIV LTR expression yet suppresses de novo infection.
Other structurally related compounds such as polymethylene
bisacetamide (55) and diethyl bis-(pentamethylene-N,N-di-
methylcarboxamide) malonate demonstrate effects similar to
the effect of HMBA on cell metabolism (56). Therefore, al-
though HMBA itself might be too toxic for immediate clinical
use (2), it may represent a prototype pharmacophore for re-
agents to approach the difficult goal of depleting the HIV-1
latent reservoir.
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